Seeking Alpha

QualityStocks'  Instablog

Send Message
QualityStocks ( assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Advaxis, Inc. (ADXS) Presents Immunotherapy Abstracts And Details Trial On Canine Osteosarcoma Study 0 comments
    Oct 29, 2012 10:18 AM | about stocks: ADXS

    Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. The company's immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the bacteria to the cancer itself.

    Advaxis was chosen to present, in oral and poster form, two abstracts detailing research with Advaxis Lm-LLO immunotherapies. The presentation was held at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting, October 26-28, 2012, at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, MD. This announcement was first made back in August, when the company first received word of being selected.

    "With the clinical data to be presented at SITC, Advaxis continues to demonstrate the utility of our novel technology for the treatment of cancer," said Dr. John Rothman, EVP of Science and Operations at Advaxis. "The commitment of Advaxis to develop new and potentially more versatile strains of Listeria to treat disease is exemplified by the work we will present on a bivalent Lm-LLO vector."

    On September 10th, Thomas Moore, Chairman and CEO of Advaxis, presented at the Rodman & Renshaw 14th Annual Healthcare Conference in the Palm Room of the Waldorf-Astoria Hotel in New York. Slides from the presentation were made available on the Advaxis website.

    Additionally, Advaxis recently announced exciting news that the first two dogs have been dosed in the University of Pennsylvania School of Veterinary Medicine study of ADXS-HER2 for canine osteosarcoma. Overseen by Dr. Nichola Mason, Chairman Companion Animal Medicine at the University of Pennsylvania School of Veterinary Medicine, ADXS-HER2 is being used to treat dogs suffering from bone cancer. Canine osteosarcoma, which causes tumors to form on long leg bones, is a leading killer of large breed dogs. Previously, the only treatment for this disease was immediate amputation of the limb, combined with follow-up chemotherapy. The recurring issue is that, typically, the cancer metastasizes and spreads to the lungs, causing death in 6-12 months.

    However, using Advaxis agent ADXS-HER2, the trial hopes to improve the lifespan of dogs exhibiting osteosarcoma. This immunotherapy is designed to stimulate the dog's immune system to attack cancer cells that express the HER-2/neu marker. The primary goal being to elicit anti-tumor immunity and prolong survival.

    "We don't have to wait years to see if we are having an effect," stated Dr. Nicola Mason. "If we find that these canine patients survive over 12 months, then that is a strong indication that this immunotherapy is in fact providing a therapeutic benefit."

    For more information on Advaxis, visit

    Please see disclaimer on the QualityStocks website:

    Stocks: ADXS
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.